463 related articles for article (PubMed ID: 17387335)
1. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
Doering CB; Gangadharan B; Dukart HZ; Spencer HT
Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
[TBL] [Abstract][Full Text] [Related]
2. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A.
Ide LM; Iwakoshi NN; Gangadharan B; Jobe S; Moot R; McCarty D; Doering CB; Spencer HT
J Gene Med; 2010 Apr; 12(4):333-44. PubMed ID: 20209485
[TBL] [Abstract][Full Text] [Related]
3. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.
Gangadharan B; Parker ET; Ide LM; Spencer HT; Doering CB
Blood; 2006 May; 107(10):3859-64. PubMed ID: 16449528
[TBL] [Abstract][Full Text] [Related]
4. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.
Ide LM; Gangadharan B; Chiang KY; Doering CB; Spencer HT
Blood; 2007 Oct; 110(8):2855-63. PubMed ID: 17569821
[TBL] [Abstract][Full Text] [Related]
5. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity.
Chen J; Schroeder JA; Luo X; Montgomery RR; Shi Q
J Thromb Haemost; 2019 Mar; 17(3):449-459. PubMed ID: 30609275
[TBL] [Abstract][Full Text] [Related]
6. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity.
Shi Q; Fahs SA; Wilcox DA; Kuether EL; Morateck PA; Mareno N; Weiler H; Montgomery RR
Blood; 2008 Oct; 112(7):2713-21. PubMed ID: 18495954
[TBL] [Abstract][Full Text] [Related]
7. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.
Kuether EL; Schroeder JA; Fahs SA; Cooley BC; Chen Y; Montgomery RR; Wilcox DA; Shi Q
J Thromb Haemost; 2012 Aug; 10(8):1570-80. PubMed ID: 22632092
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
[TBL] [Abstract][Full Text] [Related]
9. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
[TBL] [Abstract][Full Text] [Related]
10. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
11. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
[TBL] [Abstract][Full Text] [Related]
12. Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.
Doering CB; Denning G; Dooriss K; Gangadharan B; Johnston JM; Kerstann KW; McCarty DA; Spencer HT
Mol Ther; 2009 Jul; 17(7):1145-54. PubMed ID: 19259064
[TBL] [Abstract][Full Text] [Related]
13. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
Evans GL; Morgan RA
Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
[TBL] [Abstract][Full Text] [Related]
14. Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.
Doering CB; Denning G; Shields JE; Fine EJ; Parker ET; Srivastava A; Lollar P; Spencer HT
Hum Gene Ther; 2018 Oct; 29(10):1183-1201. PubMed ID: 30160169
[TBL] [Abstract][Full Text] [Related]
15. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
[TBL] [Abstract][Full Text] [Related]
16. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
[TBL] [Abstract][Full Text] [Related]
18. Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice.
Ye P; Thompson AR; Sarkar R; Shen Z; Lillicrap DP; Kaufman RJ; Ochs HD; Rawlings DJ; Miao CH
Mol Ther; 2004 Jul; 10(1):117-26. PubMed ID: 15233948
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors.
Matsui H; Shibata M; Brown B; Labelle A; Hegadorn C; Andrews C; Hebbel RP; Galipeau J; Hough C; Lillicrap D
Stem Cells; 2007 Oct; 25(10):2660-9. PubMed ID: 17615271
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
